Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic

The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra López-Matencio, José M., Gómez, Manuel, Vicente-Rabaneda, Esther F., González-Gay, Miguel A., Ancochea, Julio, Castañeda, Santos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400767/
https://www.ncbi.nlm.nih.gov/pubmed/34451916
http://dx.doi.org/10.3390/ph14080819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400767/
https://www.ncbi.nlm.nih.gov/pubmed/34451916
http://dx.doi.org/10.3390/ph14080819

Ejemplares similares